[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100476984":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":46,"collaborators":10,"id":48,"slug":10,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":10,"overallStatus":63,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Pierre Fabre Medicament","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Neratinib extended ajuvant treatmeng for 1 year",null,[12],"Drug: Neratinib",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Neratinib","Neratinib standard dose 240 mg once daily for 1 year",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Huanying Zhen, Master","CONTACT","+86010-8534-7209","nlx-pms@pierre-fabre.com",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Shujie Pei, Master","+86-13648686390","shujie.pei@clinflash.com",[30],{"facility":31,"status":10,"city":32,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Medical Affair","Shanghai","China","CN",{"type":36,"coordinates":37},"Point",[38,39],121.45806,31.22222,{"lat":39,"lon":38},[42,44],{"name":21,"role":22,"phone":43,"phoneExt":10,"email":24},"010-85347209",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":45},"Shujie.pei@clinflash.com",{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100476984",false,"NCT05491057","Treatment Patterns of Neratinib in HER2+ EBC in China","A Multicenter, Open-label, Single-arm, Non-interventional Study to Investigate the Treatment Patterns of Nerlynx® (Neratinib) in HER2-positive Early-stage Breast Cancer in China","Inclusion Criteria:\n\n* Signed written informed consent approved by the reviewing Ethics Committee (EC).\n* Adult patients (≥18 years of age, no upper limit).\n* Eligible to receive neratinib for extended adjuvant treatment as per prescribing information in China, diagnosed with HER2 overexpressing\u002Famplified early-stage breast cancer regardless of hormone receptor (HR) status and clinical\u002Fradiological assessed to be negative for recurrences or metastatic disease.\n\nExclusion Criteria:\n\n* Presence of any contraindication with regard to the neratinib treatment.\n* Current or upcoming participation in an interventional clinical trial. (Investigational treatment within four weeks of enrolment).","ALL","18 Years",{"count":57,"type":58},500,"ESTIMATED","OBSERVATIONAL","This is a multicenter, open-label, single-arm, non-interventional study to investigate the treatment patterns of Neratinib in HER2-positive early-stage breast cancer in China",[62],"Breast Cancer","NOT_YET_RECRUITING","2022-08-04",{"date":66,"type":67},"2022-08-08","ACTUAL",{"date":69,"type":58},"2022-09-30",{"date":71,"type":58},"2026-06-30",{"name":5,"class":6},1]